#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=While most nAChR agonists and antagonists binding at ACh orthosteric sites are basic molecules with at least one ionizable N , there are exceptions , including lophotoxin , the neonicotinoids and some recently synthesized pyrimidine agonists .
2-1	14-19	While	_	_	_	_
2-2	20-24	most	abstract[3]	new[3]	coref	2-32[13_3]
2-3	25-30	nAChR	abstract|abstract[3]	new|new[3]	coref	13-9
2-4	31-39	agonists	abstract[3]	new[3]	_	_
2-5	40-43	and	_	_	_	_
2-6	44-55	antagonists	substance	new	coref	2-13[7_0]
2-7	56-63	binding	_	_	_	_
2-8	64-66	at	_	_	_	_
2-9	67-70	ACh	place|place[6]	new|new[6]	coref|coref	7-27|9-32[82_6]
2-10	71-82	orthosteric	place[6]	new[6]	_	_
2-11	83-88	sites	place[6]	new[6]	_	_
2-12	89-92	are	_	_	_	_
2-13	93-98	basic	substance[7]	giv[7]	_	_
2-14	99-108	molecules	substance[7]	giv[7]	_	_
2-15	109-113	with	substance[7]	giv[7]	_	_
2-16	114-116	at	substance[7]|abstract[8]	giv[7]|new[8]	_	_
2-17	117-122	least	substance[7]|abstract[8]	giv[7]|new[8]	_	_
2-18	123-126	one	substance[7]|abstract[8]	giv[7]|new[8]	_	_
2-19	127-136	ionizable	substance[7]|abstract[8]	giv[7]|new[8]	_	_
2-20	137-138	N	substance[7]|abstract[8]	giv[7]|new[8]	_	_
2-21	139-140	,	_	_	_	_
2-22	141-146	there	_	_	_	_
2-23	147-150	are	_	_	_	_
2-24	151-161	exceptions	abstract[9]	new[9]	_	_
2-25	162-163	,	abstract[9]	new[9]	_	_
2-26	164-173	including	abstract[9]	new[9]	_	_
2-27	174-184	lophotoxin	abstract[9]|substance	new[9]|new	_	_
2-28	185-186	,	abstract[9]	new[9]	_	_
2-29	187-190	the	abstract[9]|substance[11]	new[9]|new[11]	_	_
2-30	191-205	neonicotinoids	abstract[9]|substance[11]	new[9]|new[11]	_	_
2-31	206-209	and	abstract[9]	new[9]	_	_
2-32	210-214	some	abstract[9]|abstract[13]	new[9]|giv[13]	coref	13-9[113_13]
2-33	215-223	recently	abstract[9]|abstract[13]	new[9]|giv[13]	_	_
2-34	224-235	synthesized	abstract[9]|abstract[13]	new[9]|giv[13]	_	_
2-35	236-246	pyrimidine	abstract[9]|abstract|abstract[13]	new[9]|new|giv[13]	_	_
2-36	247-255	agonists	abstract[9]|abstract[13]	new[9]|giv[13]	_	_
2-37	256-257	.	_	_	_	_

#Text=To optimize a molecule to serve as a drug or selective molecular probe of some receptor it is important to identify the form in which it interacts optimally with its target .
3-1	258-260	To	_	_	_	_
3-2	261-269	optimize	_	_	_	_
3-3	270-271	a	object[14]	new[14]	_	_
3-4	272-280	molecule	object[14]	new[14]	_	_
3-5	281-283	to	_	_	_	_
3-6	284-289	serve	_	_	_	_
3-7	290-292	as	_	_	_	_
3-8	293-294	a	_	_	_	_
3-9	295-299	drug	_	_	_	_
3-10	300-302	or	_	_	_	_
3-11	303-312	selective	_	_	_	_
3-12	313-322	molecular	_	_	_	_
3-13	323-328	probe	_	_	_	_
3-14	329-331	of	_	_	_	_
3-15	332-336	some	substance[15]	new[15]	coref	4-46[0_15]
3-16	337-345	receptor	substance[15]	new[15]	_	_
3-17	346-348	it	abstract	new	cata	3-17[0_17]
3-18	349-351	is	_	_	_	_
3-19	352-361	important	_	_	_	_
3-20	362-364	to	abstract[17]	new[17]	ana	3-26[0_17]
3-21	365-373	identify	abstract[17]	new[17]	_	_
3-22	374-377	the	abstract[17]|substance[18]	new[17]|new[18]	coref	4-10[27_18]
3-23	378-382	form	abstract[17]|substance[18]	new[17]|new[18]	_	_
3-24	383-385	in	_	_	_	_
3-25	386-391	which	_	_	_	_
3-26	392-394	it	abstract	giv	ana	3-30
3-27	395-404	interacts	_	_	_	_
3-28	405-414	optimally	_	_	_	_
3-29	415-419	with	_	_	_	_
3-30	420-423	its	abstract|abstract[21]	giv|new[21]	coref	4-44[36_21]
3-31	424-430	target	abstract[21]	new[21]	_	_
3-32	431-432	.	_	_	_	_

#Text=In the case of anabaseine , our identification of the cyclic iminium form as the most active ( and possibly the only ) form suggests that structural modifications that enhance the basicity of its tetrahydropyridyl nitrogen will enhance potency and possibly selectivity for the intended receptor target .
4-1	433-435	In	_	_	_	_
4-2	436-439	the	abstract[22]	new[22]	_	_
4-3	440-444	case	abstract[22]	new[22]	_	_
4-4	445-447	of	abstract[22]	new[22]	_	_
4-5	448-458	anabaseine	abstract[22]|substance	new[22]|new	coref	7-18
4-6	459-460	,	_	_	_	_
4-7	461-464	our	person|abstract[25]	acc|new[25]	ana	11-60
4-8	465-479	identification	abstract[25]	new[25]	_	_
4-9	480-482	of	abstract[25]	new[25]	_	_
4-10	483-486	the	abstract[25]|substance[27]	new[25]|giv[27]	ana	4-34[0_27]
4-11	487-493	cyclic	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-12	494-501	iminium	abstract[25]|object|substance[27]	new[25]|new|giv[27]	coref	7-15
4-13	502-506	form	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-14	507-509	as	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-15	510-513	the	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-16	514-518	most	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-17	519-525	active	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-18	526-527	(	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-19	528-531	and	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-20	532-540	possibly	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-21	541-544	the	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-22	545-549	only	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-23	550-551	)	abstract[25]|substance[27]	new[25]|giv[27]	_	_
4-24	552-556	form	_	_	_	_
4-25	557-565	suggests	_	_	_	_
4-26	566-570	that	_	_	_	_
4-27	571-581	structural	abstract[28]	new[28]	_	_
4-28	582-595	modifications	abstract[28]	new[28]	_	_
4-29	596-600	that	_	_	_	_
4-30	601-608	enhance	_	_	_	_
4-31	609-612	the	abstract[29]	new[29]	_	_
4-32	613-621	basicity	abstract[29]	new[29]	_	_
4-33	622-624	of	abstract[29]	new[29]	_	_
4-34	625-628	its	abstract[29]|substance|substance[32]	new[29]|giv|new[32]	coref	7-13[59_0]
4-35	629-646	tetrahydropyridyl	abstract[29]|abstract|substance[32]	new[29]|new|new[32]	_	_
4-36	647-655	nitrogen	abstract[29]|substance[32]	new[29]|new[32]	_	_
4-37	656-660	will	_	_	_	_
4-38	661-668	enhance	_	_	_	_
4-39	669-676	potency	abstract	new	coref	22-14[156_0]
4-40	677-680	and	_	_	_	_
4-41	681-689	possibly	abstract[34]	new[34]	_	_
4-42	690-701	selectivity	abstract[34]	new[34]	_	_
4-43	702-705	for	abstract[34]	new[34]	_	_
4-44	706-709	the	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
4-45	710-718	intended	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
4-46	719-727	receptor	abstract[34]|substance|abstract[36]	new[34]|giv|giv[36]	_	_
4-47	728-734	target	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
4-48	735-736	.	_	_	_	_

#Text=In fact , a major improvement in stability occurs with addition at the 3-position of the tetrahydropyridyl ring of an electron-conjugated system containing an aromatic ring , as in 3-(4-dimethylaminobenzylidene)-anabaseine or 3-(2,4-dimethoxybenzylidene)-anabaseine , also called GTS-21 .
5-1	737-739	In	_	_	_	_
5-2	740-744	fact	_	_	_	_
5-3	745-746	,	_	_	_	_
5-4	747-748	a	abstract[37]	new[37]	_	_
5-5	749-754	major	abstract[37]	new[37]	_	_
5-6	755-766	improvement	abstract[37]	new[37]	_	_
5-7	767-769	in	abstract[37]	new[37]	_	_
5-8	770-779	stability	abstract[37]|abstract	new[37]|new	_	_
5-9	780-786	occurs	_	_	_	_
5-10	787-791	with	_	_	_	_
5-11	792-800	addition	abstract[39]	new[39]	_	_
5-12	801-803	at	abstract[39]	new[39]	_	_
5-13	804-807	the	abstract[39]|substance[40]	new[39]|new[40]	_	_
5-14	808-818	3-position	abstract[39]|substance[40]	new[39]|new[40]	_	_
5-15	819-821	of	abstract[39]|substance[40]	new[39]|new[40]	_	_
5-16	822-825	the	abstract[39]|substance[40]|object[41]	new[39]|new[40]|new[41]	coref	5-24[43_41]
5-17	826-843	tetrahydropyridyl	abstract[39]|substance[40]|object[41]	new[39]|new[40]|new[41]	_	_
5-18	844-848	ring	abstract[39]|substance[40]|object[41]	new[39]|new[40]|new[41]	_	_
5-19	849-851	of	abstract[39]|substance[40]|object[41]	new[39]|new[40]|new[41]	_	_
5-20	852-854	an	abstract[39]|substance[40]|object[41]|abstract[42]	new[39]|new[40]|new[41]|new[42]	_	_
5-21	855-874	electron-conjugated	abstract[39]|substance[40]|object[41]|abstract[42]	new[39]|new[40]|new[41]|new[42]	_	_
5-22	875-881	system	abstract[39]|substance[40]|object[41]|abstract[42]	new[39]|new[40]|new[41]|new[42]	_	_
5-23	882-892	containing	_	_	_	_
5-24	893-895	an	object[43]	giv[43]	coref	6-7[0_43]
5-25	896-904	aromatic	object[43]	giv[43]	_	_
5-26	905-909	ring	object[43]	giv[43]	_	_
5-27	910-911	,	_	_	_	_
5-28	912-914	as	_	_	_	_
5-29	915-917	in	_	_	_	_
5-30	918-959	3-(4-dimethylaminobenzylidene)-anabaseine	_	_	_	_
5-31	960-962	or	_	_	_	_
5-32	963-1002	3-(2,4-dimethoxybenzylidene)-anabaseine	substance	new	_	_
5-33	1003-1004	,	_	_	_	_
5-34	1005-1009	also	_	_	_	_
5-35	1010-1016	called	_	_	_	_
5-36	1017-1023	GTS-21	abstract	new	_	_
5-37	1024-1025	.	_	_	_	_

#Text=These anabaseine derivatives do not undergo ring opening ( hydrolysis of the imine bond ) under physiological conditions , due to their extended π electron conjugation .
6-1	1026-1031	These	substance[46]	new[46]	ana	6-22[0_46]
6-2	1032-1042	anabaseine	substance[46]	new[46]	_	_
6-3	1043-1054	derivatives	substance[46]	new[46]	_	_
6-4	1055-1057	do	_	_	_	_
6-5	1058-1061	not	_	_	_	_
6-6	1062-1069	undergo	_	_	_	_
6-7	1070-1074	ring	object|event[48]	giv|new[48]	coref	23-15[163_0]
6-8	1075-1082	opening	event[48]	new[48]	_	_
6-9	1083-1084	(	_	_	_	_
6-10	1085-1095	hydrolysis	abstract[49]	new[49]	_	_
6-11	1096-1098	of	abstract[49]	new[49]	_	_
6-12	1099-1102	the	abstract[49]|abstract[51]	new[49]|new[51]	coref	23-20[165_51]
6-13	1103-1108	imine	abstract[49]|abstract|abstract[51]	new[49]|new|new[51]	_	_
6-14	1109-1113	bond	abstract[49]|abstract[51]	new[49]|new[51]	_	_
6-15	1114-1115	)	_	_	_	_
6-16	1116-1121	under	_	_	_	_
6-17	1122-1135	physiological	abstract[52]	new[52]	_	_
6-18	1136-1146	conditions	abstract[52]	new[52]	_	_
6-19	1147-1148	,	abstract[52]	new[52]	_	_
6-20	1149-1152	due	abstract[52]	new[52]	_	_
6-21	1153-1155	to	_	_	_	_
6-22	1156-1161	their	substance|abstract[56]	giv|new[56]	ana	7-3[0_56]
6-23	1162-1170	extended	abstract[56]	new[56]	_	_
6-24	1171-1172	π	abstract|abstract[56]	new|new[56]	_	_
6-25	1173-1181	electron	substance|abstract[56]	new|new[56]	_	_
6-26	1182-1193	conjugation	abstract[56]	new[56]	_	_
6-27	1194-1195	.	_	_	_	_

#Text=Previously , it was assumed ( but not experimentally tested ) that the cyclic iminium form of anabaseine is the one which binds avidly to the ACh binding site in nAChRs .
7-1	1196-1206	Previously	_	_	_	_
7-2	1207-1208	,	_	_	_	_
7-3	1209-1211	it	abstract	giv	_	_
7-4	1212-1215	was	_	_	_	_
7-5	1216-1223	assumed	_	_	_	_
7-6	1224-1225	(	_	_	_	_
7-7	1226-1229	but	_	_	_	_
7-8	1230-1233	not	_	_	_	_
7-9	1234-1248	experimentally	_	_	_	_
7-10	1249-1255	tested	_	_	_	_
7-11	1256-1257	)	_	_	_	_
7-12	1258-1262	that	_	_	_	_
7-13	1263-1266	the	substance[59]	giv[59]	coref	8-1[66_59]
7-14	1267-1273	cyclic	substance[59]	giv[59]	_	_
7-15	1274-1281	iminium	object|substance[59]	giv|giv[59]	coref	9-18[76_0]
7-16	1282-1286	form	substance[59]	giv[59]	_	_
7-17	1287-1289	of	substance[59]	giv[59]	_	_
7-18	1290-1300	anabaseine	substance[59]|substance	giv[59]|giv	coref	9-7[74_0]
7-19	1301-1303	is	_	_	_	_
7-20	1304-1307	the	event[61]	new[61]	_	_
7-21	1308-1311	one	event[61]	new[61]	_	_
7-22	1312-1317	which	_	_	_	_
7-23	1318-1323	binds	_	_	_	_
7-24	1324-1330	avidly	_	_	_	_
7-25	1331-1333	to	_	_	_	_
7-26	1334-1337	the	place[64]	new[64]	coref	23-32[170_64]
7-27	1338-1341	ACh	abstract|place[64]	giv|new[64]	_	_
7-28	1342-1349	binding	object|place[64]	new|new[64]	coref	9-8
7-29	1350-1354	site	place[64]	new[64]	_	_
7-30	1355-1357	in	place[64]	new[64]	_	_
7-31	1358-1364	nAChRs	place[64]|place	new[64]|new	coref	11-50
7-32	1365-1366	.	_	_	_	_

#Text=This form was modeled to fit into a muscle type homology model .
8-1	1367-1371	This	substance[66]	giv[66]	_	_
8-2	1372-1376	form	substance[66]	giv[66]	_	_
8-3	1377-1380	was	_	_	_	_
8-4	1381-1388	modeled	_	_	_	_
8-5	1389-1391	to	_	_	_	_
8-6	1392-1395	fit	_	_	_	_
8-7	1396-1400	into	_	_	_	_
8-8	1401-1402	a	object[70]	new[70]	_	_
8-9	1403-1409	muscle	object|object[70]	new|new[70]	_	_
8-10	1410-1414	type	abstract|object[70]	new|new[70]	_	_
8-11	1415-1423	homology	abstract|object[70]	new|new[70]	_	_
8-12	1424-1429	model	object[70]	new[70]	_	_
8-13	1430-1431	.	_	_	_	_

#Text=The crystal structure of the molluscan acetylcholine binding protein binding anabaseine actually was derived from crystals containing both the cyclic iminium and the open-chain monocationic form of anabaseine occupying some of the five identical binding sites .
9-1	1432-1435	The	abstract[71]	new[71]	coref	11-33[94_71]
9-2	1436-1443	crystal	abstract[71]	new[71]	_	_
9-3	1444-1453	structure	abstract[71]	new[71]	_	_
9-4	1454-1456	of	abstract[71]	new[71]	_	_
9-5	1457-1460	the	abstract[71]	new[71]	_	_
9-6	1461-1470	molluscan	abstract[71]	new[71]	_	_
9-7	1471-1484	acetylcholine	abstract[71]|substance[74]	new[71]|giv[74]	coref	9-28[0_74]
9-8	1485-1492	binding	abstract[71]|object|substance[74]	new[71]|giv|giv[74]	coref	9-35
9-9	1493-1500	protein	abstract[71]|substance|substance[74]	new[71]|new|giv[74]	_	_
9-10	1501-1508	binding	abstract[71]|substance[74]	new[71]|giv[74]	_	_
9-11	1509-1519	anabaseine	abstract[71]|substance[74]	new[71]|giv[74]	_	_
9-12	1520-1528	actually	_	_	_	_
9-13	1529-1532	was	_	_	_	_
9-14	1533-1540	derived	_	_	_	_
9-15	1541-1545	from	_	_	_	_
9-16	1546-1554	crystals	object	new	coref	11-5[89_0]
9-17	1555-1565	containing	_	_	_	_
9-18	1566-1570	both	object[76]|abstract[77]	giv[76]|new[77]	ana|coref	9-30[80_77]|10-2[83_76]
9-19	1571-1574	the	object[76]|abstract[77]	giv[76]|new[77]	_	_
9-20	1575-1581	cyclic	object[76]|abstract[77]	giv[76]|new[77]	_	_
9-21	1582-1589	iminium	object[76]|abstract[77]	giv[76]|new[77]	_	_
9-22	1590-1593	and	abstract[77]	new[77]	_	_
9-23	1594-1597	the	abstract[77]|substance[78]	new[77]|new[78]	coref	11-29[93_78]
9-24	1598-1608	open-chain	abstract[77]|substance[78]	new[77]|new[78]	_	_
9-25	1609-1621	monocationic	abstract[77]|substance[78]	new[77]|new[78]	_	_
9-26	1622-1626	form	abstract[77]|substance[78]	new[77]|new[78]	_	_
9-27	1627-1629	of	abstract[77]|substance[78]	new[77]|new[78]	_	_
9-28	1630-1640	anabaseine	abstract[77]|substance[78]|substance	new[77]|new[78]|giv	coref	11-44
9-29	1641-1650	occupying	_	_	_	_
9-30	1651-1655	some	abstract[80]	giv[80]	_	_
9-31	1656-1658	of	abstract[80]	giv[80]	_	_
9-32	1659-1662	the	abstract[80]|place[82]	giv[80]|giv[82]	coref	11-16[91_82]
9-33	1663-1667	five	abstract[80]|place[82]	giv[80]|giv[82]	_	_
9-34	1668-1677	identical	abstract[80]|place[82]	giv[80]|giv[82]	_	_
9-35	1678-1685	binding	abstract[80]|object|place[82]	giv[80]|giv|giv[82]	coref	23-35
9-36	1686-1691	sites	abstract[80]|place[82]	giv[80]|giv[82]	_	_
9-37	1692-1693	.	_	_	_	_

#Text=Unlike the cyclic iminium , the ammonium-ketone form ammonium group did not insert into the “ aromatic box . ”
10-1	1694-1700	Unlike	_	_	_	_
10-2	1701-1704	the	object[83]	giv[83]	coref	22-21[0_83]
10-3	1705-1711	cyclic	object[83]	giv[83]	_	_
10-4	1712-1719	iminium	object[83]	giv[83]	_	_
10-5	1720-1721	,	_	_	_	_
10-6	1722-1725	the	person[85]	new[85]	_	_
10-7	1726-1741	ammonium-ketone	person[85]	new[85]	_	_
10-8	1742-1746	form	person[85]	new[85]	_	_
10-9	1747-1755	ammonium	object|person[85]	new|new[85]	_	_
10-10	1756-1761	group	person[85]	new[85]	_	_
10-11	1762-1765	did	_	_	_	_
10-12	1766-1769	not	_	_	_	_
10-13	1770-1776	insert	_	_	_	_
10-14	1777-1781	into	_	_	_	_
10-15	1782-1785	the	object[86]	new[86]	coref	23-28[167_86]
10-16	1786-1787	“	object[86]	new[86]	_	_
10-17	1788-1796	aromatic	object[86]	new[86]	_	_
10-18	1797-1800	box	object[86]	new[86]	_	_
10-19	1801-1802	.	_	_	_	_
10-20	1803-1804	”	_	_	_	_

#Text=In the preparation of the AChBP-anabaseine crystals very high anabaseine concentrations were used so that most of the five sites would be occupied ; therefore the presence of the ammonium-ketone form in the crystal structure does not necessarily indicate that this form of anabaseine would bind to AChBPs and nAChRs at the low concentrations of anabaseine that occur in our in vitro functional and binding studies .
11-1	1805-1807	In	_	_	_	_
11-2	1808-1811	the	abstract[87]	new[87]	_	_
11-3	1812-1823	preparation	abstract[87]	new[87]	_	_
11-4	1824-1826	of	abstract[87]	new[87]	_	_
11-5	1827-1830	the	abstract[87]|object[89]	new[87]|giv[89]	_	_
11-6	1831-1847	AChBP-anabaseine	abstract[87]|abstract|object[89]	new[87]|new|giv[89]	_	_
11-7	1848-1856	crystals	abstract[87]|object[89]	new[87]|giv[89]	_	_
11-8	1857-1861	very	animal[90]	new[90]	coref	29-20[209_90]
11-9	1862-1866	high	animal[90]	new[90]	_	_
11-10	1867-1877	anabaseine	animal[90]	new[90]	_	_
11-11	1878-1892	concentrations	animal[90]	new[90]	_	_
11-12	1893-1897	were	_	_	_	_
11-13	1898-1902	used	_	_	_	_
11-14	1903-1905	so	_	_	_	_
11-15	1906-1910	that	_	_	_	_
11-16	1911-1915	most	place[91]	giv[91]	_	_
11-17	1916-1918	of	place[91]	giv[91]	_	_
11-18	1919-1922	the	place[91]	giv[91]	_	_
11-19	1923-1927	five	place[91]	giv[91]	_	_
11-20	1928-1933	sites	place[91]	giv[91]	_	_
11-21	1934-1939	would	_	_	_	_
11-22	1940-1942	be	_	_	_	_
11-23	1943-1951	occupied	_	_	_	_
11-24	1952-1953	;	_	_	_	_
11-25	1954-1963	therefore	abstract[92]	new[92]	_	_
11-26	1964-1967	the	abstract[92]	new[92]	_	_
11-27	1968-1976	presence	abstract[92]	new[92]	_	_
11-28	1977-1979	of	abstract[92]	new[92]	_	_
11-29	1980-1983	the	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-30	1984-1999	ammonium-ketone	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-31	2000-2004	form	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-32	2005-2007	in	abstract[92]|substance[93]	new[92]|giv[93]	_	_
11-33	2008-2011	the	abstract[92]|substance[93]|abstract[94]	new[92]|giv[93]|giv[94]	_	_
11-34	2012-2019	crystal	abstract[92]|substance[93]|abstract[94]	new[92]|giv[93]|giv[94]	_	_
11-35	2020-2029	structure	abstract[92]|substance[93]|abstract[94]	new[92]|giv[93]|giv[94]	_	_
11-36	2030-2034	does	_	_	_	_
11-37	2035-2038	not	_	_	_	_
11-38	2039-2050	necessarily	_	_	_	_
11-39	2051-2059	indicate	_	_	_	_
11-40	2060-2064	that	_	_	_	_
11-41	2065-2069	this	substance[95]	new[95]	coref	17-11[137_95]
11-42	2070-2074	form	substance[95]	new[95]	_	_
11-43	2075-2077	of	substance[95]	new[95]	_	_
11-44	2078-2088	anabaseine	substance[95]|substance	new[95]|giv	coref	11-56
11-45	2089-2094	would	_	_	_	_
11-46	2095-2099	bind	_	_	_	_
11-47	2100-2102	to	_	_	_	_
11-48	2103-2109	AChBPs	abstract	new	_	_
11-49	2110-2113	and	_	_	_	_
11-50	2114-2120	nAChRs	place	giv	coref	12-10[106_0]
11-51	2121-2123	at	_	_	_	_
11-52	2124-2127	the	quantity[99]	new[99]	_	_
11-53	2128-2131	low	quantity[99]	new[99]	_	_
11-54	2132-2146	concentrations	quantity[99]	new[99]	_	_
11-55	2147-2149	of	quantity[99]	new[99]	_	_
11-56	2150-2160	anabaseine	quantity[99]|substance	new[99]|giv	coref	16-37
11-57	2161-2165	that	_	_	_	_
11-58	2166-2171	occur	_	_	_	_
11-59	2172-2174	in	_	_	_	_
11-60	2175-2178	our	person|event[102]	giv|new[102]	ana|coref	15-1|25-20[183_102]
11-61	2179-2181	in	event[102]	new[102]	_	_
11-62	2182-2187	vitro	event[102]	new[102]	_	_
11-63	2188-2198	functional	event[102]	new[102]	_	_
11-64	2199-2202	and	event[102]	new[102]	_	_
11-65	2203-2210	binding	event[102]	new[102]	_	_
11-66	2211-2218	studies	event[102]	new[102]	_	_
11-67	2219-2220	.	_	_	_	_

#Text=The ability of a variety of 2-(aryl)-1,4,5,6-tetrahydropyrmidines to block neuromuscular nAChRs and produce teratogenic effects in chick embryos was reported long ago .
12-1	2221-2224	The	abstract[103]	new[103]	_	_
12-2	2225-2232	ability	abstract[103]	new[103]	_	_
12-3	2233-2235	of	abstract[103]	new[103]	_	_
12-4	2236-2237	a	abstract[103]|abstract[104]	new[103]|new[104]	ana	13-1[110_104]
12-5	2238-2245	variety	abstract[103]|abstract[104]	new[103]|new[104]	_	_
12-6	2246-2248	of	abstract[103]|abstract[104]	new[103]|new[104]	_	_
12-7	2249-2286	2-(aryl)-1,4,5,6-tetrahydropyrmidines	abstract[103]|abstract[104]|abstract	new[103]|new[104]|new	_	_
12-8	2287-2289	to	_	_	_	_
12-9	2290-2295	block	_	_	_	_
12-10	2296-2309	neuromuscular	place[106]	giv[106]	coref	15-16[125_106]
12-11	2310-2316	nAChRs	place[106]	giv[106]	_	_
12-12	2317-2320	and	_	_	_	_
12-13	2321-2328	produce	_	_	_	_
12-14	2329-2340	teratogenic	abstract[107]	new[107]	_	_
12-15	2341-2348	effects	abstract[107]	new[107]	_	_
12-16	2349-2351	in	abstract[107]	new[107]	_	_
12-17	2352-2357	chick	abstract[107]|animal|object[109]	new[107]|new|new[109]	_	_
12-18	2358-2365	embryos	abstract[107]|object[109]	new[107]|new[109]	_	_
12-19	2366-2369	was	_	_	_	_
12-20	2370-2378	reported	_	_	_	_
12-21	2379-2383	long	_	_	_	_
12-22	2384-2387	ago	_	_	_	_
12-23	2388-2389	.	_	_	_	_

#Text=Some of these compounds were reported to be nAChR agonists .
13-1	2390-2394	Some	abstract[110]	giv[110]	_	_
13-2	2395-2397	of	abstract[110]	giv[110]	_	_
13-3	2398-2403	these	abstract[110]|substance[111]	giv[110]|new[111]	coref	16-1[126_111]
13-4	2404-2413	compounds	abstract[110]|substance[111]	giv[110]|new[111]	_	_
13-5	2414-2418	were	_	_	_	_
13-6	2419-2427	reported	_	_	_	_
13-7	2428-2430	to	_	_	_	_
13-8	2431-2433	be	_	_	_	_
13-9	2434-2439	nAChR	abstract|abstract[113]	giv|giv[113]	coref	23-33
13-10	2440-2448	agonists	abstract[113]	giv[113]	_	_
13-11	2449-2450	.	_	_	_	_

#Text=The only study of PTHP on neurons was that of Upshall et al. on leech Retzius cells .
14-1	2451-2454	The	abstract[114]	new[114]	coref	16-6[127_114]
14-2	2455-2459	only	abstract[114]	new[114]	_	_
14-3	2460-2465	study	abstract[114]	new[114]	_	_
14-4	2466-2468	of	abstract[114]	new[114]	_	_
14-5	2469-2473	PTHP	abstract[114]|abstract[115]	new[114]|new[115]	coref	15-6[0_115]
14-6	2474-2476	on	abstract[114]|abstract[115]	new[114]|new[115]	_	_
14-7	2477-2484	neurons	abstract[114]|abstract[115]|object	new[114]|new[115]|new	_	_
14-8	2485-2488	was	_	_	_	_
14-9	2489-2493	that	_	_	_	_
14-10	2494-2496	of	_	_	_	_
14-11	2497-2504	Upshall	person	new	_	_
14-12	2505-2507	et	_	_	_	_
14-13	2508-2511	al.	_	_	_	_
14-14	2512-2514	on	_	_	_	_
14-15	2515-2520	leech	person|object[119]	new|new[119]	_	_
14-16	2521-2528	Retzius	object[119]	new[119]	_	_
14-17	2529-2534	cells	object[119]	new[119]	_	_
14-18	2535-2536	.	_	_	_	_

#Text=Our results also indicate that PTHP is a potent agonist at neuronal as well as neuromuscular nAChRs .
15-1	2537-2540	Our	person|abstract[121]	giv|new[121]	_	_
15-2	2541-2548	results	abstract[121]	new[121]	_	_
15-3	2549-2553	also	_	_	_	_
15-4	2554-2562	indicate	_	_	_	_
15-5	2563-2567	that	_	_	_	_
15-6	2568-2572	PTHP	abstract	giv	coref	15-8[123_0]
15-7	2573-2575	is	_	_	_	_
15-8	2576-2577	a	abstract[123]	giv[123]	coref	17-2[134_123]
15-9	2578-2584	potent	abstract[123]	giv[123]	_	_
15-10	2585-2592	agonist	abstract[123]	giv[123]	_	_
15-11	2593-2595	at	abstract[123]	giv[123]	_	_
15-12	2596-2604	neuronal	abstract[123]|person	giv[123]|new	ana	28-1
15-13	2605-2607	as	abstract[123]	giv[123]	_	_
15-14	2608-2612	well	abstract[123]	giv[123]	_	_
15-15	2613-2615	as	abstract[123]	giv[123]	_	_
15-16	2616-2629	neuromuscular	abstract[123]|abstract[125]	giv[123]|giv[125]	coref	25-3[180_125]
15-17	2630-2636	nAChRs	abstract[123]|abstract[125]	giv[123]|giv[125]	_	_
15-18	2637-2638	.	_	_	_	_

#Text=The 2-aryl compounds reported in the Brimblecombe et al. study did not include PTHP or other compounds having a 2-(3-pyridyl)- substituent , which is known to be essential for the agonist activity of nicotine and of anabaseine .
16-1	2639-2642	The	substance[126]	giv[126]	coref	16-14[128_126]
16-2	2643-2649	2-aryl	substance[126]	giv[126]	_	_
16-3	2650-2659	compounds	substance[126]	giv[126]	_	_
16-4	2660-2668	reported	_	_	_	_
16-5	2669-2671	in	_	_	_	_
16-6	2672-2675	the	abstract[127]	giv[127]	_	_
16-7	2676-2688	Brimblecombe	abstract[127]	giv[127]	_	_
16-8	2689-2691	et	abstract[127]	giv[127]	_	_
16-9	2692-2695	al.	abstract[127]	giv[127]	_	_
16-10	2696-2701	study	abstract[127]	giv[127]	_	_
16-11	2702-2705	did	_	_	_	_
16-12	2706-2709	not	_	_	_	_
16-13	2710-2717	include	_	_	_	_
16-14	2718-2722	PTHP	substance[128]	giv[128]	_	_
16-15	2723-2725	or	substance[128]	giv[128]	_	_
16-16	2726-2731	other	substance[128]	giv[128]	_	_
16-17	2732-2741	compounds	substance[128]	giv[128]	_	_
16-18	2742-2748	having	_	_	_	_
16-19	2749-2750	a	substance[129]	new[129]	_	_
16-20	2751-2765	2-(3-pyridyl)-	substance[129]	new[129]	_	_
16-21	2766-2777	substituent	substance[129]	new[129]	_	_
16-22	2778-2779	,	_	_	_	_
16-23	2780-2785	which	_	_	_	_
16-24	2786-2788	is	_	_	_	_
16-25	2789-2794	known	_	_	_	_
16-26	2795-2797	to	_	_	_	_
16-27	2798-2800	be	_	_	_	_
16-28	2801-2810	essential	_	_	_	_
16-29	2811-2814	for	_	_	_	_
16-30	2815-2818	the	abstract[131]	new[131]	coref	26-5[188_131]
16-31	2819-2826	agonist	person|abstract[131]	new|new[131]	_	_
16-32	2827-2835	activity	abstract[131]	new[131]	_	_
16-33	2836-2838	of	abstract[131]	new[131]	_	_
16-34	2839-2847	nicotine	abstract[131]|substance	new[131]|new	_	_
16-35	2848-2851	and	_	_	_	_
16-36	2852-2854	of	_	_	_	_
16-37	2855-2865	anabaseine	substance	giv	coref	17-7
16-38	2866-2867	.	_	_	_	_

#Text=For PTHP to be equipotent with anabaseine , based on the I+ form being the only active form , its EC50 would need to be ~1/3 of the EC50 of anabaseine , since the anabaseine ( I+ ) is ~1/3 of its total concentration .
17-1	2868-2871	For	_	_	_	_
17-2	2872-2876	PTHP	abstract[134]	giv[134]	coref	18-4[149_134]
17-3	2877-2879	to	abstract[134]	giv[134]	_	_
17-4	2880-2882	be	abstract[134]	giv[134]	_	_
17-5	2883-2893	equipotent	abstract[134]	giv[134]	_	_
17-6	2894-2898	with	_	_	_	_
17-7	2899-2909	anabaseine	substance	giv	ana	17-20
17-8	2910-2911	,	_	_	_	_
17-9	2912-2917	based	_	_	_	_
17-10	2918-2920	on	_	_	_	_
17-11	2921-2924	the	substance[137]	giv[137]	coref	17-15[138_137]
17-12	2925-2927	I+	object|substance[137]	new|giv[137]	appos	17-37
17-13	2928-2932	form	substance[137]	giv[137]	_	_
17-14	2933-2938	being	_	_	_	_
17-15	2939-2942	the	substance[138]	giv[138]	coref	22-18[158_138]
17-16	2943-2947	only	substance[138]	giv[138]	_	_
17-17	2948-2954	active	substance[138]	giv[138]	_	_
17-18	2955-2959	form	substance[138]	giv[138]	_	_
17-19	2960-2961	,	_	_	_	_
17-20	2962-2965	its	substance|abstract[140]	giv|new[140]	coref|coref	17-28[142_140]|17-31
17-21	2966-2970	EC50	abstract[140]	new[140]	_	_
17-22	2971-2976	would	_	_	_	_
17-23	2977-2981	need	_	_	_	_
17-24	2982-2984	to	_	_	_	_
17-25	2985-2987	be	_	_	_	_
17-26	2988-2992	~1/3	quantity[141]	new[141]	_	_
17-27	2993-2995	of	quantity[141]	new[141]	_	_
17-28	2996-2999	the	quantity[141]|abstract[142]	new[141]|giv[142]	_	_
17-29	3000-3004	EC50	quantity[141]|abstract[142]	new[141]|giv[142]	_	_
17-30	3005-3007	of	quantity[141]|abstract[142]	new[141]|giv[142]	_	_
17-31	3008-3018	anabaseine	quantity[141]|abstract[142]|substance	new[141]|giv[142]|giv	coref	17-34[144_0]
17-32	3019-3020	,	_	_	_	_
17-33	3021-3026	since	_	_	_	_
17-34	3027-3030	the	substance[144]	giv[144]	ana	17-42[0_144]
17-35	3031-3041	anabaseine	substance[144]	giv[144]	_	_
17-36	3042-3043	(	_	_	_	_
17-37	3044-3046	I+	abstract	giv	_	_
17-38	3047-3048	)	_	_	_	_
17-39	3049-3051	is	_	_	_	_
17-40	3052-3056	~1/3	_	_	_	_
17-41	3057-3059	of	_	_	_	_
17-42	3060-3063	its	substance|abstract[147]	giv|new[147]	coref|coref	18-6[150_0]|33-33[237_147]
17-43	3064-3069	total	abstract[147]	new[147]	_	_
17-44	3070-3083	concentration	abstract[147]	new[147]	_	_
17-45	3084-3085	.	_	_	_	_

#Text=The data for PTHP and anabaseine in
18-1	3086-3089	The	abstract[148]	new[148]	_	_
18-2	3090-3094	data	abstract[148]	new[148]	_	_
18-3	3095-3098	for	abstract[148]	new[148]	_	_
18-4	3099-3103	PTHP	abstract[148]|abstract[149]	new[148]|giv[149]	coref	22-8[0_149]
18-5	3104-3107	and	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
18-6	3108-3118	anabaseine	abstract[148]|abstract[149]|substance[150]	new[148]|giv[149]|giv[150]	coref	28-32[0_150]
18-7	3119-3121	in	abstract[148]|abstract[149]|substance[150]	new[148]|giv[149]|giv[150]	_	_

#Text=Figure 3
19-1	3122-3128	Figure	abstract[151]	new[151]	_	_
19-2	3129-3130	3	abstract[151]	new[151]	_	_

#Text=and
20-1	3131-3134	and	_	_	_	_

#Text=Figure 4
21-1	3135-3141	Figure	abstract[152]	new[152]	_	_
21-2	3142-3143	4	abstract[152]	new[152]	_	_

#Text=and in Table 1 , indicate that PTHP has approximately 30 % of the potency predicted for the anabaseine cyclic iminium form .
22-1	3144-3147	and	_	_	_	_
22-2	3148-3150	in	_	_	_	_
22-3	3151-3156	Table	object[153]	new[153]	_	_
22-4	3157-3158	1	object[153]	new[153]	_	_
22-5	3159-3160	,	_	_	_	_
22-6	3161-3169	indicate	_	_	_	_
22-7	3170-3174	that	_	_	_	_
22-8	3175-3179	PTHP	object	giv	_	_
22-9	3180-3183	has	_	_	_	_
22-10	3184-3197	approximately	quantity[155]	new[155]	_	_
22-11	3198-3200	30	quantity[155]	new[155]	_	_
22-12	3201-3202	%	quantity[155]	new[155]	_	_
22-13	3203-3205	of	quantity[155]	new[155]	_	_
22-14	3206-3209	the	quantity[155]|abstract[156]	new[155]|giv[156]	coref	23-5[160_156]
22-15	3210-3217	potency	quantity[155]|abstract[156]	new[155]|giv[156]	_	_
22-16	3218-3227	predicted	_	_	_	_
22-17	3228-3231	for	_	_	_	_
22-18	3232-3235	the	substance[158]	giv[158]	coref	27-11[194_158]
22-19	3236-3246	anabaseine	substance[158]	giv[158]	_	_
22-20	3247-3253	cyclic	substance[158]	giv[158]	_	_
22-21	3254-3261	iminium	object|substance[158]	giv|giv[158]	_	_
22-22	3262-3266	form	substance[158]	giv[158]	_	_
22-23	3267-3268	.	_	_	_	_

#Text=One possible explanation for this slightly inferior potency is that the additional N on the tetrahydropyrmidinyl ring must form an H bond with some other atom within the aromatic box of the nAChR orthosteric binding site and this may be energetically unfavorable .
23-1	3269-3272	One	abstract[159]	new[159]	_	_
23-2	3273-3281	possible	abstract[159]	new[159]	_	_
23-3	3282-3293	explanation	abstract[159]	new[159]	_	_
23-4	3294-3297	for	abstract[159]	new[159]	_	_
23-5	3298-3302	this	abstract[159]|abstract[160]	new[159]|giv[160]	coref	24-4[173_160]
23-6	3303-3311	slightly	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
23-7	3312-3320	inferior	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
23-8	3321-3328	potency	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
23-9	3329-3331	is	_	_	_	_
23-10	3332-3336	that	_	_	_	_
23-11	3337-3340	the	abstract[161]	new[161]	_	_
23-12	3341-3351	additional	abstract[161]	new[161]	_	_
23-13	3352-3353	N	abstract[161]	new[161]	_	_
23-14	3354-3356	on	abstract[161]	new[161]	_	_
23-15	3357-3360	the	abstract[161]|object[163]	new[161]|giv[163]	_	_
23-16	3361-3381	tetrahydropyrmidinyl	abstract[161]|abstract|object[163]	new[161]|new|giv[163]	_	_
23-17	3382-3386	ring	abstract[161]|object[163]	new[161]|giv[163]	_	_
23-18	3387-3391	must	_	_	_	_
23-19	3392-3396	form	_	_	_	_
23-20	3397-3399	an	abstract[165]	giv[165]	coref	33-7[230_165]
23-21	3400-3401	H	person|abstract[165]	new|giv[165]	_	_
23-22	3402-3406	bond	abstract[165]	giv[165]	_	_
23-23	3407-3411	with	_	_	_	_
23-24	3412-3416	some	substance[166]	new[166]	_	_
23-25	3417-3422	other	substance[166]	new[166]	_	_
23-26	3423-3427	atom	substance[166]	new[166]	_	_
23-27	3428-3434	within	_	_	_	_
23-28	3435-3438	the	object[167]	giv[167]	ana	23-38[0_167]
23-29	3439-3447	aromatic	object[167]	giv[167]	_	_
23-30	3448-3451	box	object[167]	giv[167]	_	_
23-31	3452-3454	of	object[167]	giv[167]	_	_
23-32	3455-3458	the	object[167]|place[170]	giv[167]|giv[170]	coref	33-16[233_170]
23-33	3459-3464	nAChR	object[167]|abstract|place[170]	giv[167]|giv|giv[170]	coref	33-17
23-34	3465-3476	orthosteric	object[167]|place[170]	giv[167]|giv[170]	_	_
23-35	3477-3484	binding	object[167]|object|place[170]	giv[167]|giv|giv[170]	_	_
23-36	3485-3489	site	object[167]|place[170]	giv[167]|giv[170]	_	_
23-37	3490-3493	and	_	_	_	_
23-38	3494-3498	this	object	giv	_	_
23-39	3499-3502	may	_	_	_	_
23-40	3503-3505	be	_	_	_	_
23-41	3506-3519	energetically	_	_	_	_
23-42	3520-3531	unfavorable	_	_	_	_
23-43	3532-3533	.	_	_	_	_

#Text=While 2,3′-bipyridyl displayed only a marginal potency at vertebrate receptors that could be predicted from its pKa , it has been found to be quite paralytic to insects and crustaceans .
24-1	3534-3539	While	_	_	_	_
24-2	3540-3554	2,3′-bipyridyl	organization	new	coref	27-5
24-3	3555-3564	displayed	_	_	_	_
24-4	3565-3569	only	abstract[173]	giv[173]	ana	24-16[0_173]
24-5	3570-3571	a	abstract[173]	giv[173]	_	_
24-6	3572-3580	marginal	abstract[173]	giv[173]	_	_
24-7	3581-3588	potency	abstract[173]	giv[173]	_	_
24-8	3589-3591	at	abstract[173]	giv[173]	_	_
24-9	3592-3602	vertebrate	abstract[173]|event[174]	giv[173]|new[174]	_	_
24-10	3603-3612	receptors	abstract[173]|event[174]	giv[173]|new[174]	_	_
24-11	3613-3617	that	_	_	_	_
24-12	3618-3623	could	_	_	_	_
24-13	3624-3626	be	_	_	_	_
24-14	3627-3636	predicted	_	_	_	_
24-15	3637-3641	from	_	_	_	_
24-16	3642-3645	its	abstract|abstract[176]	giv|new[176]	ana	24-19
24-17	3646-3649	pKa	abstract[176]	new[176]	_	_
24-18	3650-3651	,	_	_	_	_
24-19	3652-3654	it	abstract	giv	_	_
24-20	3655-3658	has	_	_	_	_
24-21	3659-3663	been	_	_	_	_
24-22	3664-3669	found	_	_	_	_
24-23	3670-3672	to	_	_	_	_
24-24	3673-3675	be	_	_	_	_
24-25	3676-3681	quite	_	_	_	_
24-26	3682-3691	paralytic	_	_	_	_
24-27	3692-3694	to	_	_	_	_
24-28	3695-3702	insects	animal	new	_	_
24-29	3703-3706	and	_	_	_	_
24-30	3707-3718	crustaceans	animal	new	_	_
24-31	3719-3720	.	_	_	_	_

#Text=At least some arthropod nAChRs are known to not require a cationic ligand for activation , as shown by many studies with neonicotinoid insecticides such as imidachloprid .
25-1	3721-3723	At	_	_	_	_
25-2	3724-3729	least	_	_	_	_
25-3	3730-3734	some	abstract[180]	giv[180]	coref	26-9[189_180]
25-4	3735-3744	arthropod	abstract[180]	giv[180]	_	_
25-5	3745-3751	nAChRs	abstract[180]	giv[180]	_	_
25-6	3752-3755	are	_	_	_	_
25-7	3756-3761	known	_	_	_	_
25-8	3762-3764	to	_	_	_	_
25-9	3765-3768	not	_	_	_	_
25-10	3769-3776	require	_	_	_	_
25-11	3777-3778	a	substance[181]	new[181]	_	_
25-12	3779-3787	cationic	substance[181]	new[181]	_	_
25-13	3788-3794	ligand	substance[181]	new[181]	_	_
25-14	3795-3798	for	substance[181]	new[181]	_	_
25-15	3799-3809	activation	substance[181]|event	new[181]|new	_	_
25-16	3810-3811	,	_	_	_	_
25-17	3812-3814	as	_	_	_	_
25-18	3815-3820	shown	_	_	_	_
25-19	3821-3823	by	_	_	_	_
25-20	3824-3828	many	event[183]	giv[183]	_	_
25-21	3829-3836	studies	event[183]	giv[183]	_	_
25-22	3837-3841	with	event[183]	giv[183]	_	_
25-23	3842-3855	neonicotinoid	event[183]|object|animal[185]	giv[183]|new|new[185]	_	_
25-24	3856-3868	insecticides	event[183]|animal[185]	giv[183]|new[185]	_	_
25-25	3869-3873	such	event[183]|animal[185]	giv[183]|new[185]	_	_
25-26	3874-3876	as	event[183]|animal[185]	giv[183]|new[185]	_	_
25-27	3877-3890	imidachloprid	event[183]|animal[185]|substance	giv[183]|new[185]|new	_	_
25-28	3891-3892	.	_	_	_	_

#Text=These neonicotinoids also display a limited activity at vertebrate nAChRs .
26-1	3893-3898	These	substance[187]	new[187]	_	_
26-2	3899-3913	neonicotinoids	substance[187]	new[187]	_	_
26-3	3914-3918	also	_	_	_	_
26-4	3919-3926	display	_	_	_	_
26-5	3927-3928	a	abstract[188]	giv[188]	_	_
26-6	3929-3936	limited	abstract[188]	giv[188]	_	_
26-7	3937-3945	activity	abstract[188]	giv[188]	_	_
26-8	3946-3948	at	abstract[188]	giv[188]	_	_
26-9	3949-3959	vertebrate	abstract[188]|place[189]	giv[188]|giv[189]	ana	27-1[0_189]
26-10	3960-3966	nAChRs	abstract[188]|place[189]	giv[188]|giv[189]	_	_
26-11	3967-3968	.	_	_	_	_

#Text=It seems likely that 2,3′-bipyridyl affects some arthropod nAChRs through its unionized form .
27-1	3969-3971	It	place	giv	coref	27-7[192_0]
27-2	3972-3977	seems	_	_	_	_
27-3	3978-3984	likely	_	_	_	_
27-4	3985-3989	that	_	_	_	_
27-5	3990-4004	2,3′-bipyridyl	abstract	giv	_	_
27-6	4005-4012	affects	_	_	_	_
27-7	4013-4017	some	abstract[192]	giv[192]	ana	27-11[0_192]
27-8	4018-4027	arthropod	abstract[192]	giv[192]	_	_
27-9	4028-4034	nAChRs	abstract[192]	giv[192]	_	_
27-10	4035-4042	through	_	_	_	_
27-11	4043-4046	its	place|substance[194]	giv|giv[194]	coref	33-28[236_194]
27-12	4047-4056	unionized	substance[194]	giv[194]	_	_
27-13	4057-4061	form	substance[194]	giv[194]	_	_
27-14	4062-4063	.	_	_	_	_

#Text=One can speculate as to what advantage(s) might accrue to an organism ( in this case , a hoplonemertine or ant ) to produce and secrete an imine-bond containing toxin like anabaseine .
28-1	4064-4067	One	person	giv	_	_
28-2	4068-4071	can	_	_	_	_
28-3	4072-4081	speculate	_	_	_	_
28-4	4082-4084	as	_	_	_	_
28-5	4085-4087	to	_	_	_	_
28-6	4088-4092	what	_	_	_	_
28-7	4093-4105	advantage(s)	abstract	new	_	_
28-8	4106-4111	might	_	_	_	_
28-9	4112-4118	accrue	_	_	_	_
28-10	4119-4121	to	_	_	_	_
28-11	4122-4124	an	animal[197]	new[197]	coref	34-4[246_197]
28-12	4125-4133	organism	animal[197]	new[197]	_	_
28-13	4134-4135	(	_	_	_	_
28-14	4136-4138	in	_	_	_	_
28-15	4139-4143	this	abstract[198]	new[198]	_	_
28-16	4144-4148	case	abstract[198]	new[198]	_	_
28-17	4149-4150	,	_	_	_	_
28-18	4151-4152	a	animal[199]	new[199]	_	_
28-19	4153-4167	hoplonemertine	animal[199]	new[199]	_	_
28-20	4168-4170	or	_	_	_	_
28-21	4171-4174	ant	animal	new	_	_
28-22	4175-4176	)	_	_	_	_
28-23	4177-4179	to	_	_	_	_
28-24	4180-4187	produce	_	_	_	_
28-25	4188-4191	and	_	_	_	_
28-26	4192-4199	secrete	_	_	_	_
28-27	4200-4202	an	substance[201]	new[201]	_	_
28-28	4203-4213	imine-bond	substance[201]	new[201]	_	_
28-29	4214-4224	containing	_	_	_	_
28-30	4225-4230	toxin	substance[202]	new[202]	coref	35-3[254_202]
28-31	4231-4235	like	substance[202]	new[202]	_	_
28-32	4236-4246	anabaseine	substance[202]|substance	new[202]|giv	coref	29-24
28-33	4247-4248	.	_	_	_	_

#Text=The entire body wall integument as well as the contiguous epithelium of the anterior proboscis of P. peregrina contains very high concentrations of anabaseine .
29-1	4249-4252	The	abstract[206]	new[206]	coref	31-15[223_206]
29-2	4253-4259	entire	abstract[206]	new[206]	_	_
29-3	4260-4264	body	object|abstract[206]	new|new[206]	_	_
29-4	4265-4269	wall	object|abstract[206]	new|new[206]	_	_
29-5	4270-4280	integument	abstract[206]	new[206]	_	_
29-6	4281-4283	as	_	_	_	_
29-7	4284-4288	well	_	_	_	_
29-8	4289-4291	as	_	_	_	_
29-9	4292-4295	the	place[207]	new[207]	coref	30-16[216_207]
29-10	4296-4306	contiguous	place[207]	new[207]	_	_
29-11	4307-4317	epithelium	place[207]	new[207]	_	_
29-12	4318-4320	of	place[207]	new[207]	_	_
29-13	4321-4324	the	place[207]|object[208]	new[207]|new[208]	coref	30-1[211_208]
29-14	4325-4333	anterior	place[207]|object[208]	new[207]|new[208]	_	_
29-15	4334-4343	proboscis	place[207]|object[208]	new[207]|new[208]	_	_
29-16	4344-4346	of	place[207]|object[208]	new[207]|new[208]	_	_
29-17	4347-4349	P.	place[207]|object[208]	new[207]|new[208]	_	_
29-18	4350-4359	peregrina	place[207]|object[208]	new[207]|new[208]	_	_
29-19	4360-4368	contains	_	_	_	_
29-20	4369-4373	very	animal[209]	giv[209]	_	_
29-21	4374-4378	high	animal[209]	giv[209]	_	_
29-22	4379-4393	concentrations	animal[209]	giv[209]	_	_
29-23	4394-4396	of	animal[209]	giv[209]	_	_
29-24	4397-4407	anabaseine	animal[209]|substance	giv[209]|giv	coref	34-27
29-25	4408-4409	.	_	_	_	_

#Text=The proboscis everts and wraps around the prey during its capture allowing extensive contact of this epithelium with its annelid prey .
30-1	4410-4413	The	object[211]	giv[211]	coref	31-5[220_211]
30-2	4414-4423	proboscis	object[211]	giv[211]	_	_
30-3	4424-4430	everts	_	_	_	_
30-4	4431-4434	and	_	_	_	_
30-5	4435-4440	wraps	_	_	_	_
30-6	4441-4447	around	_	_	_	_
30-7	4448-4451	the	animal[212]	new[212]	ana	30-10[0_212]
30-8	4452-4456	prey	animal[212]	new[212]	_	_
30-9	4457-4463	during	_	_	_	_
30-10	4464-4467	its	animal|event[214]	giv|new[214]	coref	30-19[218_0]
30-11	4468-4475	capture	event[214]	new[214]	_	_
30-12	4476-4484	allowing	_	_	_	_
30-13	4485-4494	extensive	abstract[215]	new[215]	_	_
30-14	4495-4502	contact	abstract[215]	new[215]	_	_
30-15	4503-4505	of	abstract[215]	new[215]	_	_
30-16	4506-4510	this	abstract[215]|place[216]	new[215]|giv[216]	_	_
30-17	4511-4521	epithelium	abstract[215]|place[216]	new[215]|giv[216]	_	_
30-18	4522-4526	with	abstract[215]|place[216]	new[215]|giv[216]	_	_
30-19	4527-4530	its	abstract[215]|place[216]|animal[218]	new[215]|giv[216]|giv[218]	coref	31-16[0_218]
30-20	4531-4538	annelid	abstract[215]|place[216]|animal|animal[218]	new[215]|giv[216]|new|giv[218]	_	_
30-21	4539-4543	prey	abstract[215]|place[216]|animal[218]	new[215]|giv[216]|giv[218]	_	_
30-22	4544-4545	.	_	_	_	_

#Text=The mineralized stylet of the proboscis can be observed to produce multiple punctures of the prey integument , which should further facilitate envenomation .
31-1	4546-4549	The	abstract[219]	new[219]	_	_
31-2	4550-4561	mineralized	abstract[219]	new[219]	_	_
31-3	4562-4568	stylet	abstract[219]	new[219]	_	_
31-4	4569-4571	of	abstract[219]	new[219]	_	_
31-5	4572-4575	the	abstract[219]|object[220]	new[219]|giv[220]	_	_
31-6	4576-4585	proboscis	abstract[219]|object[220]	new[219]|giv[220]	_	_
31-7	4586-4589	can	_	_	_	_
31-8	4590-4592	be	_	_	_	_
31-9	4593-4601	observed	_	_	_	_
31-10	4602-4604	to	_	_	_	_
31-11	4605-4612	produce	_	_	_	_
31-12	4613-4621	multiple	abstract[221]	new[221]	_	_
31-13	4622-4631	punctures	abstract[221]	new[221]	_	_
31-14	4632-4634	of	abstract[221]	new[221]	_	_
31-15	4635-4638	the	abstract[221]|abstract[223]	new[221]|giv[223]	coref	33-52[242_223]
31-16	4639-4643	prey	abstract[221]|animal|abstract[223]	new[221]|giv|giv[223]	coref	33-55[243_0]
31-17	4644-4654	integument	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
31-18	4655-4656	,	_	_	_	_
31-19	4657-4662	which	_	_	_	_
31-20	4663-4669	should	_	_	_	_
31-21	4670-4677	further	_	_	_	_
31-22	4678-4688	facilitate	_	_	_	_
31-23	4689-4701	envenomation	event	new	_	_
31-24	4702-4703	.	_	_	_	_

#Text=In addition , potential predators will also be exposed in these ways to anabaseine and related alkaloids .
32-1	4704-4706	In	_	_	_	_
32-2	4707-4715	addition	_	_	_	_
32-3	4716-4717	,	_	_	_	_
32-4	4718-4727	potential	person[225]	new[225]	_	_
32-5	4728-4737	predators	person[225]	new[225]	_	_
32-6	4738-4742	will	_	_	_	_
32-7	4743-4747	also	_	_	_	_
32-8	4748-4750	be	_	_	_	_
32-9	4751-4758	exposed	_	_	_	_
32-10	4759-4761	in	_	_	_	_
32-11	4762-4767	these	abstract[226]	new[226]	_	_
32-12	4768-4772	ways	abstract[226]	new[226]	_	_
32-13	4773-4775	to	abstract[226]	new[226]	_	_
32-14	4776-4786	anabaseine	abstract[226]|substance[227]	new[226]|new[227]	_	_
32-15	4787-4790	and	abstract[226]|substance[227]	new[226]|new[227]	_	_
32-16	4791-4798	related	abstract[226]|substance[227]	new[226]|new[227]	_	_
32-17	4799-4808	alkaloids	abstract[226]|substance[227]	new[226]|new[227]	_	_
32-18	4809-4810	.	_	_	_	_

#Text=Perhaps a major advantage of possessing an imine bond , besides an enhanced affinity for the nAChR orthosteric site , is its low basicity , which allows the unionized form to reach a relatively high concentration in the neutral pH range of the marine environment and thereby enhance passive diffusion across the integument of the prey or predator .
33-1	4811-4818	Perhaps	abstract[228]	new[228]	_	_
33-2	4819-4820	a	abstract[228]	new[228]	_	_
33-3	4821-4826	major	abstract[228]	new[228]	_	_
33-4	4827-4836	advantage	abstract[228]	new[228]	_	_
33-5	4837-4839	of	_	_	_	_
33-6	4840-4850	possessing	_	_	_	_
33-7	4851-4853	an	abstract[230]	giv[230]	_	_
33-8	4854-4859	imine	abstract|abstract[230]	new|giv[230]	_	_
33-9	4860-4864	bond	abstract[230]	giv[230]	_	_
33-10	4865-4866	,	_	_	_	_
33-11	4867-4874	besides	_	_	_	_
33-12	4875-4877	an	abstract[231]	new[231]	ana	33-22[0_231]
33-13	4878-4886	enhanced	abstract[231]	new[231]	_	_
33-14	4887-4895	affinity	abstract[231]	new[231]	_	_
33-15	4896-4899	for	abstract[231]	new[231]	_	_
33-16	4900-4903	the	abstract[231]|place[233]	new[231]|giv[233]	_	_
33-17	4904-4909	nAChR	abstract[231]|abstract|place[233]	new[231]|giv|giv[233]	_	_
33-18	4910-4921	orthosteric	abstract[231]|place[233]	new[231]|giv[233]	_	_
33-19	4922-4926	site	abstract[231]|place[233]	new[231]|giv[233]	_	_
33-20	4927-4928	,	_	_	_	_
33-21	4929-4931	is	_	_	_	_
33-22	4932-4935	its	abstract|abstract[235]	giv|new[235]	_	_
33-23	4936-4939	low	abstract[235]	new[235]	_	_
33-24	4940-4948	basicity	abstract[235]	new[235]	_	_
33-25	4949-4950	,	_	_	_	_
33-26	4951-4956	which	_	_	_	_
33-27	4957-4963	allows	_	_	_	_
33-28	4964-4967	the	substance[236]	giv[236]	_	_
33-29	4968-4977	unionized	substance[236]	giv[236]	_	_
33-30	4978-4982	form	substance[236]	giv[236]	_	_
33-31	4983-4985	to	_	_	_	_
33-32	4986-4991	reach	_	_	_	_
33-33	4992-4993	a	abstract[237]	giv[237]	_	_
33-34	4994-5004	relatively	abstract[237]	giv[237]	_	_
33-35	5005-5009	high	abstract[237]	giv[237]	_	_
33-36	5010-5023	concentration	abstract[237]	giv[237]	_	_
33-37	5024-5026	in	abstract[237]	giv[237]	_	_
33-38	5027-5030	the	abstract[237]|abstract[239]	giv[237]|new[239]	coref	34-22[252_239]
33-39	5031-5038	neutral	abstract[237]|abstract[239]	giv[237]|new[239]	_	_
33-40	5039-5041	pH	abstract[237]|quantity|abstract[239]	giv[237]|new|new[239]	coref	34-15[249_0]
33-41	5042-5047	range	abstract[237]|abstract[239]	giv[237]|new[239]	_	_
33-42	5048-5050	of	abstract[237]|abstract[239]	giv[237]|new[239]	_	_
33-43	5051-5054	the	abstract[237]|abstract[239]|place[240]	giv[237]|new[239]|new[240]	_	_
33-44	5055-5061	marine	abstract[237]|abstract[239]|place[240]	giv[237]|new[239]|new[240]	_	_
33-45	5062-5073	environment	abstract[237]|abstract[239]|place[240]	giv[237]|new[239]|new[240]	_	_
33-46	5074-5077	and	_	_	_	_
33-47	5078-5085	thereby	_	_	_	_
33-48	5086-5093	enhance	_	_	_	_
33-49	5094-5101	passive	abstract[241]	new[241]	_	_
33-50	5102-5111	diffusion	abstract[241]	new[241]	_	_
33-51	5112-5118	across	abstract[241]	new[241]	_	_
33-52	5119-5122	the	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
33-53	5123-5133	integument	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
33-54	5134-5136	of	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
33-55	5137-5140	the	abstract[241]|abstract[242]|animal[243]	new[241]|giv[242]|giv[243]	_	_
33-56	5141-5145	prey	abstract[241]|abstract[242]|animal[243]	new[241]|giv[242]|giv[243]	_	_
33-57	5146-5148	or	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
33-58	5149-5157	predator	abstract[241]|abstract[242]|animal	new[241]|giv[242]|new	_	_
33-59	5158-5159	.	_	_	_	_

#Text=The integument of a marine organism exposed to sea water is likely to have a pH near 8 , well above the pH range in which anabaseine is primarily ionized .
34-1	5160-5163	The	substance[245]	new[245]	_	_
34-2	5164-5174	integument	substance[245]	new[245]	_	_
34-3	5175-5177	of	substance[245]	new[245]	_	_
34-4	5178-5179	a	substance[245]|animal[246]	new[245]|giv[246]	_	_
34-5	5180-5186	marine	substance[245]|animal[246]	new[245]|giv[246]	_	_
34-6	5187-5195	organism	substance[245]|animal[246]	new[245]|giv[246]	_	_
34-7	5196-5203	exposed	_	_	_	_
34-8	5204-5206	to	_	_	_	_
34-9	5207-5210	sea	place|substance[248]	new|new[248]	_	_
34-10	5211-5216	water	substance[248]	new[248]	_	_
34-11	5217-5219	is	_	_	_	_
34-12	5220-5226	likely	_	_	_	_
34-13	5227-5229	to	_	_	_	_
34-14	5230-5234	have	_	_	_	_
34-15	5235-5236	a	quantity[249]	giv[249]	coref	34-23[0_249]
34-16	5237-5239	pH	quantity[249]	giv[249]	_	_
34-17	5240-5244	near	quantity[249]	giv[249]	_	_
34-18	5245-5246	8	quantity[249]|quantity	giv[249]|new	_	_
34-19	5247-5248	,	_	_	_	_
34-20	5249-5253	well	_	_	_	_
34-21	5254-5259	above	_	_	_	_
34-22	5260-5263	the	abstract[252]	giv[252]	_	_
34-23	5264-5266	pH	quantity|abstract[252]	giv|giv[252]	_	_
34-24	5267-5272	range	abstract[252]	giv[252]	_	_
34-25	5273-5275	in	_	_	_	_
34-26	5276-5281	which	_	_	_	_
34-27	5282-5292	anabaseine	substance	giv	coref	35-25
34-28	5293-5295	is	_	_	_	_
34-29	5296-5305	primarily	_	_	_	_
34-30	5306-5313	ionized	_	_	_	_
34-31	5314-5315	.	_	_	_	_

#Text=Thus , the toxin has a much better chance of entering the prey/predator than would anabaseine , the more basic secondary amine analog of anabaseine .
35-1	5316-5320	Thus	_	_	_	_
35-2	5321-5322	,	_	_	_	_
35-3	5323-5326	the	substance[254]	giv[254]	_	_
35-4	5327-5332	toxin	substance[254]	giv[254]	_	_
35-5	5333-5336	has	_	_	_	_
35-6	5337-5338	a	abstract[255]	new[255]	_	_
35-7	5339-5343	much	abstract[255]	new[255]	_	_
35-8	5344-5350	better	abstract[255]	new[255]	_	_
35-9	5351-5357	chance	abstract[255]	new[255]	_	_
35-10	5358-5360	of	_	_	_	_
35-11	5361-5369	entering	_	_	_	_
35-12	5370-5373	the	_	_	_	_
35-13	5374-5387	prey/predator	_	_	_	_
35-14	5388-5392	than	_	_	_	_
35-15	5393-5398	would	_	_	_	_
35-16	5399-5409	anabaseine	_	_	_	_
35-17	5410-5411	,	_	_	_	_
35-18	5412-5415	the	substance[257]	new[257]	_	_
35-19	5416-5420	more	substance[257]	new[257]	_	_
35-20	5421-5426	basic	substance[257]	new[257]	_	_
35-21	5427-5436	secondary	substance[257]	new[257]	_	_
35-22	5437-5442	amine	abstract|substance[257]	new|new[257]	_	_
35-23	5443-5449	analog	substance[257]	new[257]	_	_
35-24	5450-5452	of	substance[257]	new[257]	_	_
35-25	5453-5463	anabaseine	substance[257]|substance	new[257]|giv	_	_
35-26	5464-5465	.	_	_	_	_
